摘要
目的:探讨急性缺血性脑卒中患者采用依达拉奉右莰醇联合丁苯酞治疗对临床效果及S100β蛋白水平的影响。方法:选取2021年1月—2023年1月济宁市第三人民医院收治的104例急性缺血性脑卒中患者,以随机数字表法分成研究组(n=52)与对照组(n=52),对照组给予丁苯酞治疗,研究组给予依达拉奉右莰醇联合丁苯酞治疗,比较两组临床疗效、神经功能、日常生活能力、S100β蛋白水平及不良反应。结果:研究组治疗总有效率(94.23%)较对照组(78.85%)更高,差异有统计学意义(P<0.05);治疗后两组Barthel指数评分均提高,美国国立卫生研究院卒中量表(NIHSS)评分均降低,研究组Barthel指数评分较对照组更高,NIHSS评分较对照组更低,差异均有统计学意义(P<0.05);治疗后两组S100β蛋白水平均降低,研究组较对照组更低,差异均有统计学意义(P<0.05);研究组不良反应发生率(7.69%)与对照组(13.46%)比较差异无统计学意义(P>0.05)。结论:依达拉奉右莰醇联合丁苯酞用于治疗急性缺血性脑卒中,能够提高临床效果,改善神经功能及S100β蛋白水平,促进日常生活能力提升,避免加重机体不良反应。
Objective:To investigate the effect of Edaravone and Dexborneol combined with Butylphthalein on clinical effect and S100β protein level in patients with acute ischemic stroke.Method:A total of 104 patients with acute ischemic stroke admitted to Jining Third People's Hospital from January 2021 to January 2023 were selected and divided into study group(n=52)and control group(n=52)by random number table method.The control group was treated with Butylphthalein,and the study group was treated with Edaravone and Dexborneol combined with Butylphthalein.The clinical efficacy,neurological function,daily living ability,S100β protein level and adverse reactions were compared between the two groups.Result:The total effective rate of the study group(94.23%)was higher than that of the control group(78.85%),the difference was statistically significant(P<0.05).After treatment,the Barthel index scores of both groups were increased,and the national institutes of health stroke scale(NIHSS)scores were decreased,the Barthel index score of the study group was higher than that of the control group,and the NIHSS score was lower than that of the control group,the differences were statistically significant(P<0.05).After treatment,S100β protein levels were decreased in both groups,and the level in the study group was lower than that in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the study group(7.69%)and the control group(13.46%)(P>0.05).Conclusion:Edaravone and Dexborneol combined with Butylphthalein in the treatment of acute ischemic stroke can improve clinical effect,improve nerve function and S100βprotein level,promote the improvement of daily living ability,and avoid aggravating adverse reactions.
作者
王朝娜
杨雪华
WANG Chaona;YANG Xuehua(Department of Neurology,Jining Third People's Hospital,Jining 272100,China;不详)
出处
《中国医学创新》
CAS
2024年第11期10-13,共4页
Medical Innovation of China
作者简介
通信作者:王朝娜。
